Ultragenyx UK

Itraconazole (ITRACAP, internal code 199/12013) is a small-molecule antifungal agent under development by Ultragenyx UK Limited for the treatment of histoplasmosis. The program is currently in Phase 2 development with a latest milestone recorded on 9 June 2006. Itraconazole is administered via injection and represents a therapeutic approach to a serious systemic fungal infection. The drug has an established regulatory history, with approved formulations marketed in Australia under multiple sponsors and approved in the United States across multiple generic and branded applications. The Phase 2 program for histoplasmosis, associated with clinical trial NCT00004811, represents a specific development initiative by Ultragenyx UK Limited. The regulatory landscape shows itraconazole is approved in Australia (first listed 1 April 2016 and 1 December 2016) and in the United States under numerous ANDA and NDA applications. Clinical trials in China (NCT04627129, NCT07134465) indicate ongoing investigational activity in additional markets. The program's current status is listed as completed, with the most recent disclosed activity dating to mid-2006.

Histoplasmosis is a serious systemic fungal infection caused by Histoplasma capsulatum, endemic in certain geographic regions and presenting significant morbidity and mortality in immunocompromised populations, including those with HIV/AIDS. The disease requires effective antifungal therapy, and treatment options remain limited. Itraconazole's intravenous formulation addresses the need for parenteral antifungal therapy in acute or severe histoplasmosis cases where oral administration is not feasible. The competitive landscape includes fluconazole, also in Phase 2 development under Ultragenyx UK Limited, suggesting a focused development strategy around azole antifungals for this indication. The regulatory approvals of itraconazole in Australia and the United States demonstrate established manufacturing and quality standards, supporting the credibility of the histoplasmosis development program. The presence of active clinical trials in China indicates potential for geographic expansion of antifungal treatment options in markets with endemic histoplasmosis. Patient populations include both immunocompromised and immunocompetent individuals with severe or disseminated disease. Commercial significance is tied to the orphan or rare disease nature of histoplasmosis in many markets, potentially supporting expedited regulatory pathways and market exclusivity considerations.

Itraconazole is a triazole antifungal small-molecule agent. The drug is formulated for intravenous injection, enabling systemic delivery for serious fungal infections. Itraconazole belongs to the azole class of antifungals, which inhibit fungal cell wall synthesis by targeting ergosterol biosynthesis. The mechanism of action and specific molecular target are not yet disclosed in available program documentation. Related therapies include fluconazole, another azole antifungal in Phase 2 development by the same sponsor for histoplasmosis.

• Modality: Small-molecule
• Route of Administration: Intravenous injection
• Drug Class: Triazole antifungal
• First Approval (Itraconazole, general): Approved in Australia and the United States; specific approval dates for the histoplasmosis indication not yet disclosed
• Patent Status: Not yet disclosed
• Mechanism of Action: Not yet disclosed for this program
• Molecular Target: Not yet disclosed for this program

United States: Itraconazole is approved via multiple ANDA (abbreviated new drug applications) and NDA (new drug applications) with application numbers including NDA020083, NDA020657, NDA020694, NDA020966, NDA022484, NDA208901, and multiple ANDAs (076104, 200463, 203445, 204672, 205080, 205573, 205724, 205991, 206410, 206741, 208481, 208591, 209460, 212239). Multiple sponsors hold approved applications, including Accord Healthcare, Alembic, Alkem Labs, Amneal Pharmaceuticals, Apotex, Janssen Pharmaceuticals, Jubilant Generics, Mayne Pharma, Mylan, Rising, Sandoz, Sebela Ireland, Strides Pharma, and Torrent.

Australia: Itraconazole is approved and listed on the Australian Register of Therapeutic Goods (ARTG) with PBS codes 10732W and 8196J. First listed dates include 1 April 2016 and 1 December 2016 under sponsors Alphapharm Pty Ltd, Arrow Pharma Pty Ltd, and Mayne Pharma International Pty Ltd.

China: Itraconazole is in clinical trials status with active trials NCT04627129 and NCT07134465.

• European Medicines Agency (EMA): Status not yet disclosed
• Pharmaceuticals and Medical Devices Agency (PMDA, Japan): Status not yet disclosed
• National Medical Products Administration (NMPA, China): Clinical trials ongoing; regulatory approval status not yet disclosed

Strategic Implications: Ultragenyx UK Limited's development of itraconazole for histoplasmosis represents a focused strategy on rare or orphan fungal infections. The parallel development of fluconazole for the same indication suggests the sponsor is evaluating multiple azole formulations and delivery routes to optimize treatment outcomes across disease severity spectra.

Competitive Implications: The established regulatory approvals of itraconazole in major markets (US, Australia) provide a foundation for accelerated development timelines and manufacturing scale-up. The presence of multiple generic manufacturers in the US market indicates robust supply chain infrastructure that could support rapid commercialization of the histoplasmosis indication.

Future Catalysts: Key milestones include Phase 2 trial completion and data readout for NCT00004811, potential Phase 3 initiation, and regulatory submissions in the US and Europe. Active clinical trials in China (NCT04627129, NCT07134465) may support geographic expansion and potential approval in additional markets.

Expected Milestones: The program's status is listed as completed, but specific trial results and regulatory next steps are not yet disclosed. Future catalysts include publication of Phase 2 efficacy and safety data, regulatory feedback from the FDA or EMA, and decisions regarding Phase 3 advancement or indication expansion.